We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Albemarle (ALB) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Albemarle (ALB - Free Report) ended the recent trading session at $93.67, demonstrating a +1.22% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.52%. Elsewhere, the Dow saw a downswing of 1.24%, while the tech-heavy Nasdaq depreciated by 0.21%.
Prior to today's trading, shares of the specialty chemicals company had lost 14.51% lagged the Basic Materials sector's loss of 9.64% and the S&P 500's loss of 1.21%.
Analysts and investors alike will be keeping a close eye on the performance of Albemarle in its upcoming earnings disclosure. The company's earnings report is set to go public on November 4, 2026. The company's earnings per share (EPS) are projected to be $2.39, reflecting a 1357.89% increase from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $1.49 billion, up 14.15% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $11.19 per share and revenue of $6.09 billion. These totals would mark changes of +1516.46% and +18.41%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for Albemarle. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.79% lower. As of now, Albemarle holds a Zacks Rank of #3 (Hold).
Investors should also note Albemarle's current valuation metrics, including its Forward P/E ratio of 8.27. This signifies a discount in comparison to the average Forward P/E of 15.6 for its industry.
We can additionally observe that ALB currently boasts a PEG ratio of 0.55. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Chemical - Diversified stocks are, on average, holding a PEG ratio of 1.2 based on yesterday's closing prices.
The Chemical - Diversified industry is part of the Basic Materials sector. This industry currently has a Zacks Industry Rank of 200, which puts it in the bottom 19% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Albemarle (ALB) Gains As Market Dips: What You Should Know
Albemarle (ALB - Free Report) ended the recent trading session at $93.67, demonstrating a +1.22% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.52%. Elsewhere, the Dow saw a downswing of 1.24%, while the tech-heavy Nasdaq depreciated by 0.21%.
Prior to today's trading, shares of the specialty chemicals company had lost 14.51% lagged the Basic Materials sector's loss of 9.64% and the S&P 500's loss of 1.21%.
Analysts and investors alike will be keeping a close eye on the performance of Albemarle in its upcoming earnings disclosure. The company's earnings report is set to go public on November 4, 2026. The company's earnings per share (EPS) are projected to be $2.39, reflecting a 1357.89% increase from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $1.49 billion, up 14.15% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $11.19 per share and revenue of $6.09 billion. These totals would mark changes of +1516.46% and +18.41%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for Albemarle. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.79% lower. As of now, Albemarle holds a Zacks Rank of #3 (Hold).
Investors should also note Albemarle's current valuation metrics, including its Forward P/E ratio of 8.27. This signifies a discount in comparison to the average Forward P/E of 15.6 for its industry.
We can additionally observe that ALB currently boasts a PEG ratio of 0.55. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Chemical - Diversified stocks are, on average, holding a PEG ratio of 1.2 based on yesterday's closing prices.
The Chemical - Diversified industry is part of the Basic Materials sector. This industry currently has a Zacks Industry Rank of 200, which puts it in the bottom 19% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.